Immunohistochemical analysis of cardiac troponin inhibitor in an experimental model of acute myocardial infarction experimental model and in human tissues

Pathology, Research and Practice
Jian-zhang JiaZi-qin Zhao

Abstract

Acute obstruction of coronary arteries leads to acute myocardial infarction (AMI), which causes unexpected death in humans. However, AMI cannot be easily detected in forensic examinations with traditional hematoxylin and eosin (H&E) staining. We analyzed whether cardiac troponin inhibitor (CTnI) could serve as a sensitive and specific early marker for diagnosing AMI in forensic medicine. We established an AMI model in rabbits by ligating the left ventricular branch and observed CTnI expression with immunohistochemistry after different ligation times. We found increased CTnI staining at the 0.5-h time point and depletion of CTnI staining with a 1-h ligation. The areas in which CTnI staining was depleted as seen with immunohistochemical analysis were consistent with the results of H&E staining. Next, human myocardium tissues from 30 persons who died from AMI and were subsequently examined in our forensic center were studied using immunohistochemistry with an antibody to human CTnI. Areas of infarction also showed depletion of CTnI staining. These findings suggested that immunohistochemical detection of CTnI is earlier, more sensitive, and myocardial tissue - specific as compared with H&E staining. CTnI may serve as an ideal marke...Continue Reading

References

Apr 23, 1996·Forensic Science International : Synergy·B J HuJ Z Zhu
Dec 12, 2003·Cardiology in Review·Srinivasa PotluriMandeep R Mehra
Nov 5, 2004·Molecular and Cellular Biochemistry·Martin E CullenPaul J R Barton
Feb 1, 2005·The Annals of Thoracic Surgery·Joseph F SabikDelos M Cosgrove
Jun 2, 2005·Circulation·Douglas L Mann, Michael R Bristow
Sep 1, 2007·Current Opinion in Cardiology·Cinzia Perrino, Howard A Rockman
Jun 4, 2008·The American Journal of Forensic Medicine and Pathology·Carlo P CampobassoMassimo F Colonna
Aug 28, 2009·The New England Journal of Medicine·Till KellerStefan Blankenberg
Apr 28, 2010·Nature Reviews. Cardiology·Sumeet S Chugh
Oct 4, 2011·Clinical Chemistry·Fred S AppleUNKNOWN IFCC Task Force on Clinical Applications of Cardiac Biomarkers
Feb 1, 2012·CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne·Sally J AldousMartin Than
Feb 21, 2014·Brazilian Journal of Medical and Biological Research = Revista Brasileira De Pesquisas Médicas E Biológicas·X J ZhaoH P Xu

❮ Previous
Next ❯

Citations

Jun 28, 2016·Laboratory Medicine·Sultan PehlivanOmer Akyol
Jan 25, 2018·International Journal of Legal Medicine·Aleksandra AljaknaSara Sabatasso
Aug 11, 2018·Applied Immunohistochemistry & Molecular Morphology : AIMM·Rosario Barranco, Francesco Ventura
Feb 12, 2020·Applied Immunohistochemistry & Molecular Morphology : AIMM·Rosario Barranco, Francesco Ventura
Nov 26, 2016·International Journal of Legal Medicine·Cristina MondelloElvira Ventura-Spagnolo

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiomyopathy

Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.

Biomarkers for Cardiovascular Risk Assessment

Sensitive and accurate biomarkers used in cardiovascular risk prediction can potentially be used to manage the risk of cardiovascular disease. Discover the latest research on Biomarkers for Cardiovascular Risk Assessment here. Discover the latest research on Biomarkers for Cardiovascular Risk Assessment here.